

Dystonia

Precision Panel



Overview

Dystonia is a heterogeneous movement disorder featuring sustained or intermittent muscle contractions causing abnormal, often repetitive movements, postures or both. Dystonic movements are typically patterned and twisting, even tremulous. It is generally initiated or worsened by voluntary action and associated with overflow muscle activation. Out of the different types of dystonia, focal dystonia, more specifically cervical dystonia is the most common and is approximately 10 times more frequent than generalized dystonia. Their clinical heterogeneity accounts for a profound effect on the personal, vocational, and emotional life of a patient and can impact greatly his/her ability to live independently. Dystonia may be inherited, acquired, or idiopathic. A strong genetic component has been identified in familial dystonia syndromes.

The Igenomix Dystonia Precision Panel can serve as an accurate and directed diagnostic tool ultimately as well as a differential diagnosis of muscle cramps leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.

Indications

The Igenomix Dystonia Precision Panel is indicated in patients with a clinical suspicion or diagnosis presenting with or without the following manifestations:

- Uncontrolled muscle cramps and spasms
- Body twisting and unusual positions
- Shaking (tremors)
- Uncontrolled blinking

Clinical Utility

The clinical utility of this panel is:

- The genetic and molecular diagnosis for an accurate clinical diagnosis of a symptomatic patient.
- Early initiation of treatment with a multidisciplinary team in the form of pharmacologic therapy with anticholinergics, intramuscular botulinum toxin injection and/or deep brain stimulation.

- Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance.
- Improvement of delineation of genotype-phenotype correlation.

Genes & Diseases

GENE	OMIM DISEASES	INHERITANCE*	% GENE COVERAGE (20X)	HGMD**
<i>ACTB</i>	Baraitser-Winter Syndrome, Dystonia, Becker Nevus Syndrome, Developmental Malformations, Deafness	AD	100	40 of 40
<i>ADCY5</i>	Dyskinesia, Facial Myokymia, Chorea	AD	94.14	30 of 30
<i>ANO3</i>	Dystonia	AD	99.95	30 of 30
<i>ATP1A3</i>	Alternating Hemiplegia Of Childhood, Cerebellar Ataxia, Pes Cavus, Optic Atrophy, Sensorineuralhearing Loss, Dystonia, Parkinson Disease	AD	99.94	138 of 138
<i>ATP7B</i>	Wilson Disease	AR	99.97	989 of 1000
<i>BCAP31</i>	Deafness, Dystonia, Cerebral Hypomyelination, Motor And Intellectual Disabilities	X,XR,G	100	-
<i>CACNA1B</i>	Neurodevelopmental Disorder, Seizures, Hyperkinetic Movements, Epileptic Encephalopathy	AR	95.83	7 of 7
<i>CACNA1G</i>	Spinocerebellar Ataxia, Neurodevelopmental Deficits	AD	99.52	16 of 16
<i>CIZ1</i>	Cervical Dystonia	-	100	3 of 3
<i>COL6A3</i>	Bethlem Myopathy, Dystonia, Ullrich Congenital Muscular Dystrophy	AD,AR	99.63	232 of 232
<i>CYP27A1</i>	Cerebrotendinous Xanthomatosis	AR	100	118 of 118
<i>DCAF17</i>	Woodhouse-Sakati Syndrome	AR	98.77	21 of 21
<i>DDC</i>	Aromatic L-Amino Acid Decarboxylase Deficiency	AR	100	59 of 59
<i>DNAJC12</i>	Hyperphenylalaninemia	AR	81.82	10 of 10
<i>DRD2</i>	Myoclonus-Dystonia Syndrome	-	100	4 of 4
<i>DRD5</i>	Attention Deficit-Hyperactivity Disorder, Blepharospasm	AD	98.8	-
<i>FA2H</i>	Spastic Paraplegia, Fatty Acid Hydroxylase-Associated Neurodegeneration	AR	88.77	60 of 62
<i>FITM2</i>	Siddiqi Syndrome	AR	99.97	3 of 3
<i>GCH1</i>	Dystonia, Gtp Cyclohydrolase I Deficiency	AD,AR	99.41	225 of 244
<i>GNAL</i>	Dystonia	AD	90.85	34 of 35
<i>GNAO1</i>	Epileptic Encephalopathy, Neurodevelopmental Disorder	AD	100	47 of 47
<i>HEXA</i>	Tay-Sachs Disease	AR	100	205 of 206
<i>HPCA</i>	Dystonia	AR	99.98	6 of 6
<i>KCNMA1</i>	Cerebellar Atrophy, Developmental Delay, Seizures, Epilepsy, Paroxysmal Dyskinesia, Liang-Wang Syndrome	AD,AR	99.98	24 of 26
<i>KCTD17</i>	Dystonia	AD	93.61	3 of 3
<i>KMT2B</i>	Dystonia	AD	95.88	61 of 62
<i>MECR</i>	Dystonia, Optic Atrophy, Basal Ganglia Abnormalities	AR	100	8 of 8
<i>MED20</i>	Waardenburg Syndrome	-	99.98	2 of 2
<i>MIPEP</i>	Oxidative Phosphorylation Deficiency	AR	99.84	7 of 8
<i>PANK2</i>	Hypoprebetalipoproteinemia, Acanthocytosis, Retinitis Pigmentosa, Pallidal Degeneration, Neurodegeneration, Brain Iron Accumulation	AR	98.92	177 of 182
<i>PDE10A</i>	Dyskinesia, Striatal Degeneration, Chorea	AD,AR	100	8 of 8
<i>PDGFB</i>	Basal Ganglia Calcification, Meningioma, Bilateral Striopallidodentate Calcinosi, Dermatofibrosarcoma Protuberans	AD	100	22 of 22
<i>PDGFRB</i>	Basal Ganglia Calcification, Kosaki Overgrowth Syndrome, Myeloproliferative Disorder, Myofibromatosis, Premature Aging Syndrome, Bilateral Striopallidodentate Calcinosi	AD	99.64	28 of 28




PLA2G6	Neuroaxonal Dystrophy, Neurodegeneration, Brain Iron Accumulation, Parkinson Disease, Dystonia, Parkinson Disease	AR	99.94	190 of 191
PNKD	Paroxysmal Nonkinesigenic Dyskinesia	AD	99.98	6 of 6
PRKN	Lung Cancer, Parkinson Disease	AD,AR	100	-
PRKRA	Dystonia	AR	100	9 of 9
PRRT2	Convulsions, Paroxysmal Choreoathetosis, Kinesigenic Dyskinesia, Epilepsy, Hemiplegic Migraine	AD	99.93	111 of 111
SCP2	Leukoencephalopathy, Dystonia, Motor Neuropathy	AR	100	5 of 5
SGCE	Myoclonic Dystonia	AD	99.46	94 of 98
SLC2A1	Choreoathetosis, Spasticity, Epilepsy, Glucose Transport Defect, Glut1 Deficiency Syndrome, Stomatin-Deficient Cryohydrocytosis, Childhood Absence Epilepsy, Dyskinesia	AD,AR	99.99	301 of 304
SLC30A10	Hyper manganeseemia, Dystonia, Polycythemia, Cirrhosis	AR	100	19 of 19
SLC39A14	Hyper manganeseemia, Dystonia, Hyperostosis Cranialis Interna, Parkinson Disease	AD,AR	100	9 of 9
SLC6A3	Parkinson Disease, Dystonia	AR	100	31 of 31
SPR	Dystonia, Sepiapterin Reductase Deficiency	AD,AR	99.89	27 of 27
TAF1	Dystonia, Mental Retardation, Parkinson Disease, Global Development Delay, Facial Dysmorphism	X,XR,G	99.74	-
TH	Segawa Syndrome, Dystonia	AR	100	71 of 71
THAP1	Dystonia	AD	99.94	96 of 98
TOR1A	Arthrogryposis Multiplex Congenita, Dystonia	AD,AR	100	17 of 18
TOR1AIP1	Limb Girdle Muscular Dystrophy	AR	97.5	5 of 6
TUBB4A	Dystonia Musculorum Deformans, Leukodystrophy	AD	89.81	44 of 44
UBTF	Neurodegeneration, Brain Atrophy, Motor And Cognitive Regression Syndrome	AD	99.99	2 of 2
VAC14	Striatonigral Degeneration, Yunis-Varon Syndrome	AR	100	11 of 11
VPS13A	Choreoacanthocytosis	AR	99.37	120 of 122
VPS13D	Spinocerebellar Ataxia	AR	99.97	19 of 19
XPR1	Basal Ganglia Calcification, Bilateral Striopallidodentate Calcinosi	AD	99.88	14 of 14

*Inheritance: AD: Autosomal Dominant; AR: Autosomal Recessive; X: X linked; XLR: X linked Recessive; Mi: Mitochondrial; Mu: Multifactorial.

**Number of clinically relevant mutations according to HGMD

Methodology



Contact us

Call +34 963 905 310 or send an email to supportspain@igenomix.com for any of the following objectives:

- Get more information about the test.
- Request your kit.
- Request a pick up of the kit after collecting the sample.

References

1. Skogseid I. M. (2014). Dystonia--new advances in classification, genetics, pathophysiology and treatment. *Acta neurologica Scandinavica. Supplementum*, (198), 13–19. <https://doi.org/10.1111/ane.12231>
2. Lohmann, K., & Klein, C. (2017). Update on the Genetics of Dystonia. *Current neurology and neuroscience reports*, 17(3), 26. <https://doi.org/10.1007/s11910-017-0735-0>
3. Steeves, T., Day, L., Dykeman, J., Jette, N., & Pringsheim, T. (2021). The prevalence of primary dystonia: A systematic review and meta-analysis. Retrieved 31 March 2021
4. Vidailhet, M., Méneret, A., & Roze, E. (2020). Dystonia: genetics, phenomenology, and pathophysiology. *The Lancet. Neurology*, 19(11), 881–882. [https://doi.org/10.1016/S1474-4422\(20\)30366-5](https://doi.org/10.1016/S1474-4422(20)30366-5)
5. Balint, B., Mencacci, N. E., Valente, E. M., Pisani, A., Rothwell, J., Jankovic, J., Vidailhet, M., & Bhatia, K. P. (2018). Dystonia. *Nature reviews. Disease primers*, 4(1), 25. <https://doi.org/10.1038/s41572-018-0023-6>
6. Albanese, A., Barnes, M., Bhatia, K., Fernandez-Alvarez, E., Filippini, G., & Gasser, T. et al. (2006). A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. *European Journal Of Neurology*, 13(5), 433-444. doi: 10.1111/j.1468-1331.2006.01537.x
7. Schwarz, C. S., & Bressman, S. B. (2009). Genetics and treatment of dystonia. *Neurologic clinics*, 27(3), 697–vi. <https://doi.org/10.1016/j.ncl.2009.04.010>